Adult men and women (=18 years).
Receptors of a first kidney transplant from an incompatible HLA living donor (at least 1 mismatch HLA at any antigenic level).
AB0 compatible transplant.
Patients with a calculated PRA of 0% by solid phase technique and absence of anti-HLA class I and class II antibodies by single antigen test (Luminex®).
Patients who agree to participate in the Trial by signing the Specific Informed Consent of this study.
Potentially fertile women should use high reliability contraceptive methods (Pearl-Index <1) in order to avoid pregnancy during the entire duration of the study and up to 6 weeks after the end of their treatment with Mycophenolate Mofetil (MMF). Potentially Fertile Women include any woman who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or who is not post-menopausal (defined as amenorrhea = 12 consecutive months, or women who are receiving hormone replacement therapy with a documented level of follicle stimulating hormone (FSH)> 35 mlU / ml). Potentially fertile women must have a pregnancy test with a negative result in the 72 hours prior to the start of the trial.
Sexually active males (including vasectomized males) who are being treated with MMF must accept the use of barrier contraceptive methods during MMF treatment and for 90 days thereafter. Potentially fertile partners of these patients should use a reliable contraceptive method during the same period, in order to minimize the risk of pregnancy.
Patients must agree not to donate blood during treatment with MMF and during the 6 subsequent weeks. Males should not make a sperm donation during MMF treatment and up to 90 days after completion.

NCT03465397_inc_T1
Person
men
NCT03465397_inc_T2
Person
Adult
NCT03465397_inc_T3
Person
women
NCT03465397_inc_T4
Value
=18 years
NCT03465397_inc_T5
Person
years
NCT03465397_inc_T6
Procedure
first kidney transplant
NCT03465397_inc_T7
Qualifier
incompatible HLA
NCT03465397_inc_T8
Qualifier
living donor
NCT03465397_inc_T9
Multiplier
at least 1
NCT03465397_inc_T10
Observation
mismatch HLA
NCT03465397_inc_T11
Qualifier
AB0 compatible
NCT03465397_inc_T12
Procedure
transplant
NCT03465397_inc_T13
Measurement
calculated PRA
NCT03465397_inc_T14
Value
0%
NCT03465397_inc_T15
Qualifier
solid phase technique
NCT03465397_inc_T16
Procedure
single antigen test (Luminex®)
NCT03465397_inc_T17
Observation
absence of anti-HLA class I
NCT03465397_inc_T18
Observation
ence of an ss II an
NCT03465397_inc_T19
Scope
absence of anti-HLA class I and class II